420 related articles for article (PubMed ID: 30659428)
1. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
2. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
3. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
[TBL] [Abstract][Full Text] [Related]
4. Second rebound-associated vertebral fractures after denosumab discontinuation.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
[TBL] [Abstract][Full Text] [Related]
5. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
6. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
7. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
Diédhiou D; Cuny T; Sarr A; Norou Diop S; Klein M; Weryha G
Ann Endocrinol (Paris); 2015 Dec; 76(6):650-7. PubMed ID: 26639186
[TBL] [Abstract][Full Text] [Related]
9. [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?].
Lamy O; Gonzalez Rodriguez E; Stoll D; Aubry-Rozier B; Livio F
Praxis (Bern 1994); 2018 Jun; 107(12):649-654. PubMed ID: 29871576
[TBL] [Abstract][Full Text] [Related]
10. Drug holidays in women treated for postmenopausal osteoporosis.
McClung MR
Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
[TBL] [Abstract][Full Text] [Related]
11. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report.
Mori Y; Izumiyama T; Mori N; Aizawa T
Tohoku J Exp Med; 2021 May; 254(1):57-61. PubMed ID: 34053968
[TBL] [Abstract][Full Text] [Related]
13. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
[TBL] [Abstract][Full Text] [Related]
14. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
15. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Popp AW; Zysset PK; Lippuner K
Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
[TBL] [Abstract][Full Text] [Related]
16. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
[No Abstract] [Full Text] [Related]
17. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature.
Florez H; Ramírez J; Monegal A; Guañabens N; Peris P
Semin Arthritis Rheum; 2019 Oct; 49(2):197-203. PubMed ID: 30826108
[TBL] [Abstract][Full Text] [Related]
18. Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
Anastasilakis AD; Trovas G; Balanika A; Polyzos SA; Makras P; Tournis S
J Clin Densitom; 2021; 24(2):338-340. PubMed ID: 33218880
[TBL] [Abstract][Full Text] [Related]
19. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Tsourdi E; Langdahl B; Cohen-Solal M; Aubry-Rozier B; Eriksen EF; Guañabens N; Obermayer-Pietsch B; Ralston SH; Eastell R; Zillikens MC
Bone; 2017 Dec; 105():11-17. PubMed ID: 28789921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]